4//SEC Filing
Ratliff John D 4
Accession 0001127602-19-005195
CIK 0000920148other
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 7:59 PM ET
Size
12.8 KB
Accession
0001127602-19-005195
Insider Transaction Report
Form 4
Ratliff John D
CEO, Covance Drug Development
Transactions
- Exercise/Conversion
Common Stock
2019-02-07+1,863→ 11,261 total - Tax Payment
Common Stock
2019-02-07$147.46/sh−556$81,988→ 10,665 total - Exercise/Conversion
Restricted Stock Unit
2019-02-07−1,863→ 24,474 total→ Common Stock (1,863 underlying)
Holdings
- 40(indirect: By Trust)
Common Stock
- 80(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- [F2]Stock withholding to satisfy tax withholding obligations.
- [F3]In prior Section 16 reports shares were previously also reported in shares shown as directly owned.
- [F4]The reporting person is not a trustee of the irrevocable trust and disclaims beneficial ownership of the shares.
- [F5]The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/7/18.
- [F6]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
Issuer
LABORATORY CORP OF AMERICA HOLDINGS
CIK 0000920148
Entity typeother
Related Parties
1- filerCIK 0001575951
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 7:59 PM ET
- Size
- 12.8 KB